Amela Biosciences AG

Designed cell matrices for reproducible in vitro biology

Swiss Startup - Amela Biosciences Main Image

Amela Biosciences develops designed, animal-free protein bioinks for reproducible 3D cell culture and biofabrication. Batch-to-batch variability and reliance on animal-derived materials present central challenges for reproducibility and standardisation in cell research. Amela Biosciences' protein bioinks enable researchers and industry partners to work with tailored, fully defined materials, advancing the transition to human-relevant research. The technology originates from ETH Zurich and is protected by patents. The team combines expertise in protein design, biotechnology, and business. Amela Biosciences is headquartered at Switzerland Innovation Park Ost in St. Gallen. The market for bioinks and 3D cell culture is projected to exceed USD 1 billion by 2030.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No news

No milestones

No Jobs

No videos and documents

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Venture Kick (10'000) 2026

Website